Movatterモバイル変換


[0]ホーム

URL:


CN113444730A - Screening and constructing method of primary hepatocyte klotho gene transduction stem cells - Google Patents

Screening and constructing method of primary hepatocyte klotho gene transduction stem cells
Download PDF

Info

Publication number
CN113444730A
CN113444730ACN202110288118.9ACN202110288118ACN113444730ACN 113444730 ACN113444730 ACN 113444730ACN 202110288118 ACN202110288118 ACN 202110288118ACN 113444730 ACN113444730 ACN 113444730A
Authority
CN
China
Prior art keywords
klotho
gene
htert
stem cells
transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110288118.9A
Other languages
Chinese (zh)
Inventor
贾政
刘茜
杨文慧
吴剑
王洪涛
李华
张丽
陈志鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yanan Hospital of Kunming City
Original Assignee
Yanan Hospital of Kunming City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yanan Hospital of Kunming CityfiledCriticalYanan Hospital of Kunming City
Priority to CN202110288118.9ApriorityCriticalpatent/CN113444730A/en
Publication of CN113444730ApublicationCriticalpatent/CN113444730A/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The invention discloses a primary hepatocyte klotho gene transduction stem cell screening and constructing method in the technical field of gene transduction stem cell screening and constructing methods, which is characterized in that a polymorphic DNA sequence of a klotho gene exon 4 region is obtained through PCR amplification as a basis, a T allelic site of rs648202 is used as a drug design target spot to screen out an active molecule capable of adjusting the klotho gene expression level, a polymorphic DNA fragment is adopted to transduce human hepatocytes, and dual vectors of hTERT and pLXSN are adopted to transduce vectors, so that pLXSN-hTERT expression vector transduction of hTERT is efficiently expressed, the effect of constructing stem cells efficiently expressing klotho genes is achieved, and the survival capability of the inter-marrow stem cells transducing exogenous klotho genes is improved in a low-solubility hygromycin dual screening culture system.

Description

Screening and constructing method of primary hepatocyte klotho gene transduction stem cells
Technical Field
The invention relates to the technical field of screening and constructing methods of gene transduction stem cells, in particular to a screening and constructing method of primary hepatocyte klotho gene transduction stem cells.
Background
Primary hepatocellular carcinoma (liver cancer, HCC for short) is one of the most common malignant tumors worldwide, and the hepatitis B virus is a hepadnavirus, can cause various diseases such as acute and chronic hepatitis, cirrhosis and the like, and has a very close relationship with the occurrence of hepatocellular carcinoma; in addition, Klotho is a gene discovered to be related to aging in 1997, is located on human chromosome 13q12, is about 50kb in length, consists of 5 exons and 4 introns, and the Klotho gene is lack of expression in mice to cause various phenotypes similar to human aging.
The existing stem cell in vitro amplification technical methods can be roughly classified into two types: the first method is to add different combinations of recombinant cell growth factors in a culture system, aiming at utilizing the cell growth factors to properly regulate and control the proliferation and differentiation of stem cells, and the technical method can improve the expansion multiple of the stem cells to a certain extent, but if the types of the cell factors in the combination are too few, the ideal expansion effect is difficult to achieve, and if the types of the cell factors are too many, the combination is difficult to apply in clinical transplantation because of high cost; the second type is a method developed in recent years, i.e. bone marrow stromal stem cells are used to simulate the in vivo cell growth and differentiation environment to promote the rapid expansion and functional activation, but in this method, because some cytokines (such as TPO and FL) in bone marrow stromal stem cells are expressed very slightly, exogenous cytokines are still added in an expansion culture system to assist, and in combination with the application of klotho gene in treating tumors, klotho gene is integrated and expressed in human target cell nucleus, which can lead to the change of cell proliferation activity and show various tumor-related transformation phenotypes, so that stem cells obtain the capability of unlimited proliferation and are immortalized, and the most commonly used technology for immortalizing cells is to support the in vitro expansion capability of stem cells by constructing an expression vector containing telomerase catalytic subunit (hTERT) and transfecting cells by various methods, therefore, a screening and constructing method of primary hepatocyte klotho gene transduction stem cells is provided.
Disclosure of Invention
The invention aims to provide a screening and constructing method of primary hepatocyte klotho gene transduction stem cells, so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a primary hepatocyte klotho gene transduction stem cell screening and constructing method, the specific steps of the transduction stem cell method are:
s1: taking human whole genome DNA to be detected containing klotho gene as a template, then obtaining a polymorphic DNA sequence of a klotho gene exon 4 region through PCR amplification, wherein the DNA sequence contains rs648202 mononucleotide, then carrying out enzyme digestion on a product obtained after PCR amplification through restriction endonuclease HaeIII, and simultaneously carrying out rs648202 mononucleotide polymorphic typing through agarose gel electrophoresis to form DNA fragments with different lengths;
s2: separating mRNA from human liver cells, synthesizing corresponding cDNA by reverse transcription-polymerase chain reaction technology, connecting polymorphic DNA fragments with an Internal Ribosome Entry Site (IRES) sequence to form IRES-klotho fragments, cloning the IRES-klotho fragments into a pBluescript vector to construct IRES-klotho recombinant fragments, and transferring the IRES-klotho recombinant fragments from the pBluescript vector to a retrovirus vector pLXIN through an XhoI enzyme cleavage site to construct a pfl30 expression vector;
s3: according to the instruction manual of a LipofectAMINE liposome transduction kit, after a pLXSN-hTERT recombinant expression vector suspension is prepared by a facultative packaging cell line PA317, the pLXSN-hTERT expression vector is transduced to human stem cells for eight hours under the assistance of dimethyl dinitrogen undecyl methylene polymethine bromide based on the pLXSN vector, so that the human stem cells for efficiently expressing exogenous hTERT genes can be constructed;
s4: the technology of double screening the human stem cells transduced with the exogenous hTERT gene by adopting the hygromycin with low concentration improves the survival capability of the stem cells transduced with the exogenous hTERT gene.
The nucleotide polypeptide typing in the step S1 is specifically as follows: the length of the DNA fragment after the CC genotype is enzyme-cut is still 163bp, the DNA fragments with the three lengths of 163bp, 100bp and 63bp are generated after the CT genotype is enzyme-cut, and the DNA fragments with the two lengths of 100bp and 63bp are generated after the TT genotype is enzyme-cut.
The pBluescript vector used in the step S2, the human retrovirus vector, is pLXIN, and can obtain the pfl30 expression vector for efficiently expressing the klotho gene.
Compared with the prior art, the invention has the beneficial effects that: the invention adopts a polymorphic DNA sequence of a klotho gene exon 4 region obtained by PCR amplification as a basis, utilizes a T allelic site of rs648202 as a drug design target spot to screen drugs, screens out active molecules capable of regulating the klotho gene expression level, judges whether an individual has susceptibility to primary hepatocellular carcinoma by detecting the existence of the T allelic site, is beneficial to screening of susceptible population of the primary hepatocellular carcinoma and prevention of the primary hepatocellular carcinoma, and achieves the effect of obtaining stem cells by one-time gene transduction and simultaneously efficiently expressing exogenous klotho genes and the human hepatocytes by adopting polymorphic DNA fragment transduction based on the human hepatocytes, thereby reducing the cost of stem cell in-vitro amplification culture, effectively improving the in-vitro self-renewal, amplification and differentiation capacity of the stem cells, and adopting hTERT and pLXSN dual vectors to carry out vector transduction successively, the pLXSN-hTERT expression vector transduction for efficiently expressing hTERT is achieved, the effect of constructing the stem cell for efficiently expressing the klotho gene is achieved, the survival capability of the bone marrow mesenchymal stem cell for transducing the exogenous klotho gene is improved in a low-solubility hygromycin double-screening culture system, and the success rate of constructing the stem cell for exogenously expressing the klotho gene is improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
A primary hepatocyte klotho gene transduction stem cell screening and constructing method, a primary hepatocyte klotho gene transduction stem cell screening and constructing method, the stem cell transduction method comprises the following steps:
s1: taking human whole genome DNA to be detected containing klotho gene as a template, then obtaining a polymorphic DNA sequence of a klotho gene exon 4 region through PCR amplification, wherein the DNA sequence contains rs648202 mononucleotide, then carrying out enzyme digestion on a product obtained after PCR amplification through restriction endonuclease HaeIII, and simultaneously carrying out rs648202 mononucleotide polymorphic typing through agarose gel electrophoresis to form DNA fragments with different lengths;
s2: separating mRNA from human liver cells, synthesizing corresponding cDNA by reverse transcription-polymerase chain reaction technology, connecting polymorphic DNA fragments with an Internal Ribosome Entry Site (IRES) sequence to form IRES-klotho fragments, cloning the IRES-klotho fragments into a pBluescript vector to construct IRES-klotho recombinant fragments, and transferring the IRES-klotho recombinant fragments from the pBluescript vector to a retrovirus vector pLXIN through an XhoI enzyme cleavage site to construct a pfl30 expression vector;
s3: according to the instruction manual of a LipofectAMINE liposome transduction kit, after a pLXSN-hTERT recombinant expression vector suspension is prepared by a facultative packaging cell line PA317, the pLXSN-hTERT expression vector is transduced to human stem cells for eight hours under the assistance of dimethyl dinitrogen undecyl methylene polymethine bromide based on the pLXSN vector, so that the human stem cells for efficiently expressing exogenous hTERT genes can be constructed;
s4: the technology of double screening the human stem cells transduced with the exogenous hTERT gene by adopting the hygromycin with low concentration improves the survival capability of the stem cells transduced with the exogenous hTERT gene;
the nucleotide polypeptide typing in the step S1 is specifically as follows: the length of the DNA fragment after the CC genotype enzyme digestion is still 163bp, DNA fragments with three lengths of 163bp, 100bp and 63bp are generated after the CT genotype enzyme digestion, and DNA fragments with two lengths of 100bp and 63bp are generated after the TT genotype enzyme digestion;
the pBluescript vector used in the step S2, the human retrovirus vector, adopts pLXIN, and can obtain pfl30 expression vector for high-efficiency expression of klotho gene;
the application comprises the following steps: the nucleic acid sequence of the polymorphism sites related to the primary hepatocyte can construct a kit for genetic screening of primary hepatocyte susceptible population, and the kit is used as a target point of drug design to find out active molecules capable of regulating klotho gene expression, thereby promoting the discovery of new antitumor drugs.
The invention adopts a polymorphic DNA sequence of a klotho gene exon 4 region obtained by PCR amplification as a basis, utilizes a T allelic site of rs648202 as a drug design target spot to screen drugs, screens out active molecules capable of regulating the klotho gene expression level, judges whether an individual has susceptibility to primary hepatocellular carcinoma by detecting the existence of the T allelic site, is beneficial to screening of susceptible population of the primary hepatocellular carcinoma and prevention of the primary hepatocellular carcinoma, and achieves the effect of obtaining stem cells by one-time gene transduction and simultaneously efficiently expressing exogenous klotho genes and the human hepatocytes by adopting polymorphic DNA fragment transduction based on the human hepatocytes, thereby reducing the cost of stem cell in-vitro amplification culture, effectively improving the in-vitro self-renewal, amplification and differentiation capacity of the stem cells, and adopting hTERT and pLXSN dual vectors to carry out vector transduction successively, the pLXSN-hTERT expression vector transduction for efficiently expressing hTERT is achieved, the effect of constructing the stem cell for efficiently expressing the klotho gene is achieved, the survival capability of the bone marrow mesenchymal stem cell for transducing the exogenous klotho gene is improved in a low-solubility hygromycin double-screening culture system, and the success rate of constructing the stem cell for exogenously expressing the klotho gene is improved.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (3)

Translated fromChinese
1.一种原发性肝细胞klotho基因转导干细胞筛选构建方法,其特征在于:转导干细胞方法的具体步骤为:1. a primary hepatocyte klotho gene transduction stem cell screening construction method, is characterized in that: the concrete steps of the transduction stem cell method are:S1:以包含klotho基因的待测人全基因组DNA为模板,然后通过PCR扩增得到klotho基因外显子4区的多态DNA序列,且DNA序列包含rs648202单核苷酸,然后对PCR扩增后的产物经限制性内切酶HaeIII进行酶切,同时通过琼脂糖凝胶电泳进行rs648202单核苷酸多态分型形成不同长度的DNA片段;S1: Take the whole genome DNA to be tested containing the klotho gene as a template, and then amplify the polymorphic DNA sequence of the exon 4 region of the klotho gene by PCR, and the DNA sequence contains rs648202 single nucleotide, and then amplify the PCR The resulting product was digested by restriction endonuclease HaeIII, and at the same time, rs648202 single nucleotide polymorphism was subjected to agarose gel electrophoresis to form DNA fragments of different lengths;S2:从人体肝细胞中分离出mRNA,并通过反转录-聚合酶链反应技术合成相应的cDNA,将多态分型的DNA片段与内核糖体进入位点(IRES)序列连接形成IRES-klotho片段后再克隆到pBluescript载体中,构建成IRES-klotho重组片段,然后,IRES-klotho重组片段再从pBluescript载体通过XhoI酶切位点转移到反转录病毒载体pLXIN上,构建成pfl30表达载体;S2: mRNA is isolated from human hepatocytes, and the corresponding cDNA is synthesized by reverse transcription-polymerase chain reaction technology, and the polymorphic DNA fragment is connected with the internal ribosome entry site (IRES) sequence to form IRES- The klotho fragment was then cloned into the pBluescript vector to construct the IRES-klotho recombinant fragment. Then, the IRES-klotho recombinant fragment was transferred from the pBluescript vector to the retroviral vector pLXIN through the XhoI restriction site to construct the pfl30 expression vector ;S3:依据LipofectAMINE脂质体转导试剂盒的指导说明书,通过兼噬性包装细胞系PA317制备pLXSN-hTERT重组表达载体悬浮液后,在二甲基二氮十一亚甲基聚甲溴化物的辅助下基于pLXSN载体对人体干细胞进行八个小时的pLXSN-hTERT表达载体转导,由此可以构建高效表达外源hTERT基因的人体干细胞;S3: According to the instructions of the LipofectAMINE liposome transduction kit, after the pLXSN-hTERT recombinant expression vector suspension was prepared by the phagocytic packaging cell line PA317, the suspension of the pLXSN-hTERT recombinant expression vector was prepared in the The human stem cells were transduced with the pLXSN-hTERT expression vector for eight hours based on the pLXSN vector with the assistance, so that human stem cells highly expressing the exogenous hTERT gene could be constructed;S4:采用低浓度的潮霉素进行双重筛选转导外源hTERT基因的人体干细胞的技术,提高转导外源hTERT基因的干细胞的存活能力。S4: The technology of double screening human stem cells transduced with exogenous hTERT gene by using low concentration of hygromycin to improve the survival ability of stem cells transduced with exogenous hTERT gene.2.根据权利要求1所述的一种原发性肝细胞klotho基因转导干细胞筛选构建方法,其特征在于:S1步骤中核苷酸多肽分型具体为:CC基因型酶切后的DNA片段长度仍为163bp,CT基因型酶切后产生163bp、100bp和63bp三种长度的DNA片段,同时TT基因型酶切后产生100bp和63bp两种长度的DNA片段。2. a kind of primary hepatocyte klotho gene transduction stem cell screening construction method according to claim 1, is characterized in that: in step S1, the nucleotide and polypeptide typing is specifically: the DNA fragment length after CC genotype enzyme cut Still 163bp, the DNA fragments of 163bp, 100bp and 63bp were generated after the CT genotype digestion, and the DNA fragments of 100bp and 63bp were generated after the TT genotype digestion.3.根据权利要求1所述的一种原发性肝细胞klotho基因转导干细胞筛选构建方法,其特征在于:S2步骤中所用的pBluescript载体,人反转录病毒载体是采用pLXIN,能够获得高效表达klotho基因的pfl30表达载体。3. a kind of primary hepatocyte klotho gene transduction stem cell screening construction method according to claim 1, is characterized in that: the pBluescript carrier used in S2 step, the human retrovirus carrier adopts pLXIN, can obtain efficient The pfl30 expression vector expressing the klotho gene.
CN202110288118.9A2021-03-172021-03-17Screening and constructing method of primary hepatocyte klotho gene transduction stem cellsPendingCN113444730A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN202110288118.9ACN113444730A (en)2021-03-172021-03-17Screening and constructing method of primary hepatocyte klotho gene transduction stem cells

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN202110288118.9ACN113444730A (en)2021-03-172021-03-17Screening and constructing method of primary hepatocyte klotho gene transduction stem cells

Publications (1)

Publication NumberPublication Date
CN113444730Atrue CN113444730A (en)2021-09-28

Family

ID=77809053

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN202110288118.9APendingCN113444730A (en)2021-03-172021-03-17Screening and constructing method of primary hepatocyte klotho gene transduction stem cells

Country Status (1)

CountryLink
CN (1)CN113444730A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN112921009A (en)*2021-03-172021-06-08昆明市延安医院Cell construction method of recombinant adenovirus carrying Klotho promoter gene and application thereof

Citations (31)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB0126436D0 (en)*2001-11-032002-01-02Sequenom IncDetection of predispostion to osteoporosis
WO2004065561A2 (en)*2003-01-212004-08-05Ptc Therapeutics, Inc.Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
CN1706955A (en)*2004-06-072005-12-14成都康弘科技实业(集团)有限公司Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
US20060067890A1 (en)*2004-09-292006-03-30Oncolys Biopharma Inc.Telomelysin/GFP-expressing recombinant virus
CN1818071A (en)*2005-07-042006-08-16浙江大学Method for transferring bone marrow filling dry cell by TPO/FL
CN101063150A (en)*2007-04-242007-10-31浙江大学Method for transduction of bone marrow mesenchyma stem cell by human telomerase gene
CN101330830A (en)*2005-10-182008-12-24国家犹太医学研究中心Conditionally immortalized long-term stem cells and methods of making and using same
CN101353646A (en)*2008-03-132009-01-28首都医科大学北京神经科学研究所Telomerase immortalized human fetal forebrain neural precursor cell line and construction method thereof
WO2009046738A1 (en)*2007-10-092009-04-16Curevac GmbhComposition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CN101438158A (en)*2006-03-062009-05-20阿穆尼克斯股份有限公司Genetic packages and uses thereof
CN101974488A (en)*2010-06-212011-02-16西北农林科技大学Immortalized porcine pancreatic stem cell line and construction and differentiation methods thereof
CN102796820A (en)*2012-08-222012-11-28黄曙Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use
CN103923942A (en)*2014-05-082014-07-16扬州大学Transposable element carrier expressing pig telomerase reverse transcriptase, building method thereof and application in building pig immortalization cell line
CN103952443A (en)*2013-05-202014-07-30中国人民解放军军事医学科学院基础医学研究所Tumor-treatment adenovirus vaccine taking hTERT (human telomerase reverse transcriptase) as target point
CA2855402A1 (en)*2014-08-142016-02-14Ming JianThe formulation (formula or the prescription of ingredients) of an age defying product, which is for anti-ageing/reverse of age and correcting age associated diseases through reactiving telomere enzyme
CN106659686A (en)*2014-04-042017-05-10拉姆医疗公司An inhalable rapamycin formulation for treating age-related conditions
CN106662577A (en)*2014-01-242017-05-10恩格姆生物制药公司Binding proteins and methods of use thereof
CN107249576A (en)*2014-10-072017-10-13拉姆医疗公司Inhalable rapamycin formulation for treating pulmonary hypertension
CN107557461A (en)*2017-10-202018-01-09武汉赛云博生物科技有限公司A kind of mass spectrographic detection method of nucleic acid early sieved for liver cancer susceptibility
EP3305900A1 (en)*2005-12-012018-04-11Nuevolution A/SEnzymatic encoding methods for efficient synthesis of large libraries
CN108290941A (en)*2015-09-232018-07-17百时美施贵宝公司The seralbumin associativity fibronectin type III domain of fast dissociation rate
CN109030835A (en)*2018-09-062018-12-18江苏省人民医院(南京医科大学第附属医院)Method for analyzing effect of Rab8 on Klotho expression regulation in non-small cell lung cancer
CN109097336A (en)*2018-09-072018-12-28深圳市新仑生物科技有限公司A kind of stem cell excretion body, preparation method and application
CN109100514A (en)*2018-09-062018-12-28江苏省人民医院(南京医科大学第附属医院)Research method for analyzing Klotho interaction protein in non-small cell lung cancer
CN109219663A (en)*2016-06-022019-01-15克洛索治疗有限公司 Therapeutic recombinant KLOTHO proteins and compositions and methods thereof
CN109251896A (en)*2018-08-132019-01-22中山大学The cell strain and its preparation method and application of one Expression of Plant Height hKLs-his albumen
US20190203212A1 (en)*2012-07-252019-07-04Massachusetts Institute Of TechnologyInducible dna binding proteins and genome perturbation tools and applications thereof
US20190345224A1 (en)*2016-05-202019-11-14President And Fellows Of Harvard CollegeGene Therapy Methods for Age-Related Diseases and Conditions
CN110499331A (en)*2019-08-092019-11-26中国农业科学院兰州兽医研究所 Method for obtaining exogenous human telomerase reverse transcriptase gene recombinant lentiviral particles
CN112695049A (en)*2020-08-202021-04-23山东兴瑞生物科技有限公司Fusion gene and plasmid for modifying mesenchymal stem cell, stem cell obtained through modification and preparation method
CN113151442A (en)*2021-04-152021-07-23苏州市立医院Fluorescence composite amplification system and kit for 55 autosomal loci and application of fluorescence composite amplification system and kit

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB0126436D0 (en)*2001-11-032002-01-02Sequenom IncDetection of predispostion to osteoporosis
EP2500437A2 (en)*2003-01-212012-09-19PTC Therapeutics, Inc.Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
WO2004065561A2 (en)*2003-01-212004-08-05Ptc Therapeutics, Inc.Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
CN1706955A (en)*2004-06-072005-12-14成都康弘科技实业(集团)有限公司Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
US20060067890A1 (en)*2004-09-292006-03-30Oncolys Biopharma Inc.Telomelysin/GFP-expressing recombinant virus
CN1818071A (en)*2005-07-042006-08-16浙江大学Method for transferring bone marrow filling dry cell by TPO/FL
CN101330830A (en)*2005-10-182008-12-24国家犹太医学研究中心Conditionally immortalized long-term stem cells and methods of making and using same
EP3305900A1 (en)*2005-12-012018-04-11Nuevolution A/SEnzymatic encoding methods for efficient synthesis of large libraries
CN101438158A (en)*2006-03-062009-05-20阿穆尼克斯股份有限公司Genetic packages and uses thereof
CN101063150A (en)*2007-04-242007-10-31浙江大学Method for transduction of bone marrow mesenchyma stem cell by human telomerase gene
WO2009046738A1 (en)*2007-10-092009-04-16Curevac GmbhComposition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CN101353646A (en)*2008-03-132009-01-28首都医科大学北京神经科学研究所Telomerase immortalized human fetal forebrain neural precursor cell line and construction method thereof
CN101974488A (en)*2010-06-212011-02-16西北农林科技大学Immortalized porcine pancreatic stem cell line and construction and differentiation methods thereof
US20190203212A1 (en)*2012-07-252019-07-04Massachusetts Institute Of TechnologyInducible dna binding proteins and genome perturbation tools and applications thereof
CN102796820A (en)*2012-08-222012-11-28黄曙Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use
CN103952443A (en)*2013-05-202014-07-30中国人民解放军军事医学科学院基础医学研究所Tumor-treatment adenovirus vaccine taking hTERT (human telomerase reverse transcriptase) as target point
CN106662577A (en)*2014-01-242017-05-10恩格姆生物制药公司Binding proteins and methods of use thereof
CN106659686A (en)*2014-04-042017-05-10拉姆医疗公司An inhalable rapamycin formulation for treating age-related conditions
CN103923942A (en)*2014-05-082014-07-16扬州大学Transposable element carrier expressing pig telomerase reverse transcriptase, building method thereof and application in building pig immortalization cell line
CA2855402A1 (en)*2014-08-142016-02-14Ming JianThe formulation (formula or the prescription of ingredients) of an age defying product, which is for anti-ageing/reverse of age and correcting age associated diseases through reactiving telomere enzyme
CN107249576A (en)*2014-10-072017-10-13拉姆医疗公司Inhalable rapamycin formulation for treating pulmonary hypertension
CN108290941A (en)*2015-09-232018-07-17百时美施贵宝公司The seralbumin associativity fibronectin type III domain of fast dissociation rate
US20190345224A1 (en)*2016-05-202019-11-14President And Fellows Of Harvard CollegeGene Therapy Methods for Age-Related Diseases and Conditions
CN109219663A (en)*2016-06-022019-01-15克洛索治疗有限公司 Therapeutic recombinant KLOTHO proteins and compositions and methods thereof
CN107557461A (en)*2017-10-202018-01-09武汉赛云博生物科技有限公司A kind of mass spectrographic detection method of nucleic acid early sieved for liver cancer susceptibility
CN109251896A (en)*2018-08-132019-01-22中山大学The cell strain and its preparation method and application of one Expression of Plant Height hKLs-his albumen
CN109030835A (en)*2018-09-062018-12-18江苏省人民医院(南京医科大学第附属医院)Method for analyzing effect of Rab8 on Klotho expression regulation in non-small cell lung cancer
CN109100514A (en)*2018-09-062018-12-28江苏省人民医院(南京医科大学第附属医院)Research method for analyzing Klotho interaction protein in non-small cell lung cancer
CN109097336A (en)*2018-09-072018-12-28深圳市新仑生物科技有限公司A kind of stem cell excretion body, preparation method and application
CN110499331A (en)*2019-08-092019-11-26中国农业科学院兰州兽医研究所 Method for obtaining exogenous human telomerase reverse transcriptase gene recombinant lentiviral particles
CN112695049A (en)*2020-08-202021-04-23山东兴瑞生物科技有限公司Fusion gene and plasmid for modifying mesenchymal stem cell, stem cell obtained through modification and preparation method
CN113151442A (en)*2021-04-152021-07-23苏州市立医院Fluorescence composite amplification system and kit for 55 autosomal loci and application of fluorescence composite amplification system and kit

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JINYONG KIM 等: "Short hairpin RNA screen indicates that Klotho beta/FGF19 protein overcomes stasis in human colonic epithelial cells", 《J BIOL CHEM》*
乔梦楠: "间质细胞衰老诱导上皮细胞癌变的研究进展", 《人人健康》*
张军 等: "Klotho蛋白对高糖作用下人脐静脉血管内皮细胞凋亡和衰老的作用", 《广东医学》*
张艳芳 等: "Klotho基因对子宫颈鳞癌细胞恶性生物学行为的影响及相关机制", 《中国肿瘤生物治疗杂志》*
李桂霞等: "抗衰老及抗肿瘤中药对端粒、端粒酶影响的研究进展", 《辽宁中医杂志》*
李秀全 等: "Klotho对大鼠骨髓间充质干细胞增殖和分化的影响", 《解剖学报》*
童坦君等: "衰老相关基因研究进展", 《现代实用医学》*
黄炜 等: "人骨髓间充质干细胞的衰老机制及其"永生化"技术", 《中国组织工程研究与临床康复》*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN112921009A (en)*2021-03-172021-06-08昆明市延安医院Cell construction method of recombinant adenovirus carrying Klotho promoter gene and application thereof

Similar Documents

PublicationPublication DateTitle
Wang et al.Epigenetic targeting of granulin in hepatoma cells by synthetic CRISPR dCas9 epi-suppressors
Pitarque et al.Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity
Napoli et al.Unraveling framework of the ancestral Mediator complex in human diseases
Zhao et al.Gene Codon Composition Determines Differentiation-Dependent Expression of a Viral Capsid Gene in Keratinocytes In Vitro and InVivo
Yoshida et al.Genomic structure and promoter activity of the mouse polysialic acid synthase gene (mST8Sia II): brain-specific expression from a TATA-less GC-rich sequence
Weis et al.Stable miRNA overexpression in human CAP cells: Engineering alternative production systems for advanced manufacturing of biologics using miR‐136 and miR‐3074
CN113444730A (en)Screening and constructing method of primary hepatocyte klotho gene transduction stem cells
Li et al.Stabilizing and anti-repressor elements effectively increases transgene expression in transfected CHO cells
CN115927331A (en)DNA framework for promoting circRNA cyclization and overexpression and construction method and application thereof
WO2025087435A1 (en)Promoter element derived from asmt gene and use of promoter element
CN101954094A (en)Application of miR-199a-3p in preparation of medicine for resisting hepatitis B virus
CN109486816B (en)Polynucleotide for treating tumor and its application
Shi et al.Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP producing hepatocarcinoma cell
Chuang et al.Characterization of the promoter-regulatory region and structural organization of E1 alpha gene (BCKDHA) of human branched-chain alpha-keto acid dehydrogenase complex.
Jin et al.CRISPR/Cas9-mediated high-mobility group A2 knockout inhibits cell proliferation and invasion in papillary thyroid carcinoma cells
Mori et al.Identification of cell cycle-associated and-unassociated regulators for expression of a hepatocellular carcinoma oncogene cyclin-dependent kinase inhibitor 3
CN116024263A (en) A eukaryotic expression vector for highly expressing porcine HIF-1α gene and its construction method
CN112057608B (en) Application of KMT2D in the preparation of anti-tumor drugs
CN115851793A (en)Eukaryotic expression vector for efficiently expressing pig PFKFB3 gene and construction method thereof
Tang et al.Construction of IL-2 gene-modified human hepatocyte and its cultivation with microcarrier
EP0894866B1 (en)Tec tyrosine kinase promoter
Pan et al.Translational initiation at a non-AUG start codon for human and mouse negative elongation factor-B
CN112266932B (en)Construction of human RNF20 gene over-expression plasmid vector and its cancer cell inhibiting effect
CN105586340B (en) HER2/neu tissue-specific promoter variants and their uses
CN110042121B (en) A method for promoting differentiation of leukemia cells and its application

Legal Events

DateCodeTitleDescription
PB01Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination
RJ01Rejection of invention patent application after publication
RJ01Rejection of invention patent application after publication

Application publication date:20210928


[8]ページ先頭

©2009-2025 Movatter.jp